Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Background: We evaluated the effects of low doses of the tyrosine kinase Abelson (Abl) inhibitor Nilotinib, on safety and pharmacokinetics in Parkinson’s disease dementia or dementia with Lewy bodies.

Bibliographic Details
Main Authors: Pagan, Fernando, Hebron, Michaeline, Valadez, Ellen H., Torres-Yaghi, Yasar, Huang, Xu, Mills, Reversa R., Wilmarth, Barbara M., Howard, Hellen, Dunn, Connell, Carlson, Alexis, Lawler, Abigail, Rogers, Sean L., Falconer, Ramsey A., Ahn, Jaeil, Li, Zhaoxia, Moussa, Charbel
Format: Online
Language:English
Published: IOS Press 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008228/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008228/

Similar Items